HIGHBuilt-inProduct / Revenue mix
70%
companion animal products
“10-K Item 1: 'Companion animal products represented approximately 70% of our revenue for the year ended December 31, 2025'”
ZTS · Concentration risk · 10-K extracted
Zoetis (ZTS) concentration risks
Updated
The most significant concentration Zoetis discloses is companion animal products at 70%, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Zoetis’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 3 disclosed concentrations
HIGH2
MEDIUM1
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
HIGHBuilt-inGeographic
54%
United States
“10-K Item 1: 'United States (U.S.) with revenue of $5,097 million, or 54% of total revenue for the year ended December 31, 2025'”
MEDIUMBuilt-inProduct / Revenue mix
42%
top five product lines
“10-K Item 1A: 'our five top-selling products and product lines...contributed approximately 42% of our revenue in 2025'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-06-24The company's concentration profile reflects two overlapping structural tilts — product and geographic — plus a moderate product-line concentration within the portfolio. Companion animal products represented approximately 70% of revenue for the year ended December 31, 2025 — a large, high-share structural concentration by disclosed size. This reflects the deliberate strategic focus on dogs and cats as the primary customer end-market, and the tilt is structural: the business has been built around companion animal health, which drives the research pipeline, commercial investments, and veterinary relationships. The United States contributed 54% of total revenue for the year ended December 31, 2025 — a large, high-share structural exposure by disclosed size. A majority of revenue is earned domestically, with the remainder distributed across international markets. U.S. veterinary pricing dynamics, pet ownership trends, and reimbursement patterns are therefore the dominant determinants of results. Within the portfolio, the five top-selling products and product lines contributed approximately 42% of revenue in 2025 — a moderate, medium-share structural concentration by disclosed size. This indicates that, while the product portfolio spans a broad range of species and therapeutic areas, a relatively small number of flagships generate a disproportionate share of sales. Patent expirations or generic competition against those specific products would have a more concentrated revenue impact than the overall portfolio breadth might suggest. Together, the companion animal tilt and U.S. geographic weight point in the same direction, as the U.S. companion animal market is where both concentrations peak simultaneously.
For the engine’s reasoning on ZTS’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Drug Manufacturers - Specialty & Generic
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ANIP | ANI Pharmaceuticals, Inc. | 2 | 1 | 0 | 3 |
| ZTS● | Zoetis Inc. | 2 | 1 | 0 | 3 |
| AMLX | Amylyx Pharmaceuticals, Inc. | 2 | 0 | 0 | 2 |
| AMRX | Amneal Pharmaceuticals, Inc. | 1 | 1 | 0 | 2 |
| BCRX | BioCryst Pharmaceuticals, Inc. | 0 | 2 | 0 | 2 |
| ALKS | Alkermes plc | 0 | 1 | 1 | 2 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.